EyePoint Inc. Common Stock (EYPT)

About EYPT

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining…

Sector

Industrials

Industry

Biotechnology: Laboratory Analytical Instruments

Employees

214

Website

eyepoint.bio/

Fundamentals

1-day range

$4.36$4.67

Market cap

$1.08B

P/E (trailing)

—

P/E (forward)

-1.62

EPS (trailing)

$-3.74

Dividend yield

—

Beta

1.55

Avg. volume

3.11M

Dividend pay date

December 9, 2020

Forecasts

11 analyst ratings

EyePoint Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• EYPT

  EyePoint Inc. Common Stock

  $4.47

  ▼ 3.46%
  Market cap $1.08BP/E —
  $3.95$19.11
• CTKB

  Cytek Biosciences Inc. Common Stock

  $4.69

  ▲ 1.41%
  Market cap $537.23MP/E —
  $3.28$6.18
• PACB

  Pacific Biosciences of California Inc. Common Stock

  $1.4

  ▼ 10.00%
  Market cap $361.85MP/E —
  $1.07$2.73
• ALMR

  Alamar Biosciences Inc. Common Stock

  $30.71

  ▼ 6.94%
  Market cap $1.95BP/E —
  $18.85$38.54
• QTRX

  Quanterix Corporation Common Stock

  $2.64

  ▼ 0.00%
  Market cap $180.42MP/E —
• SEER

  Seer Inc. Class A Common Stock

  $1.99

  ▼ 1.00%
  Market cap $120.41MP/E —
• NAUT

  Nautilus Biotechnology Inc. Common Stock

  $0.8828

  ▼ 2.35%
  Market cap $112.76MP/E —
  $0.62$4.31

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward
  SeekingAlpha · 8/27/2026
• Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
  Benzinga · 8/25/2026
• EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
  SeekingAlpha · 8/19/2026
• EyePoint: Still A Sell After Phase 3 Crash
  SeekingAlpha · 8/19/2026
• These Analysts Slash Their Forecasts On EyePoint
  Benzinga · 8/18/2026
• Citigroup Maintains Buy on EyePoint, Lowers Price Target to $17
  Benzinga · 8/18/2026
• EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU - Slideshow
  SeekingAlpha · 8/18/2026
• EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript
  SeekingAlpha · 8/18/2026
• Why Is Ocular Therapeutix Stock Gaining Monday?
  benzinga · 8/17/2026

• George Elston · August 20, 2026 · Gift

  65.0K
• George Elston · August 20, 2026 · J

  5.0K
• Jay S. Duker · July 10, 2026 · Option Exercise

  16.7K
• Jay S. Duker · July 10, 2026 · Tax Withholding

  8.1K @ $14.72
• Ramiro Ribeiro · June 30, 2026 · Option Exercise

  2.4K @ $8.26
• Ramiro Ribeiro · June 30, 2026 · Option Exercise

  2.4K @ $8.26
• Ramiro Ribeiro · June 30, 2026 · Sale

  2.4K @ $15.02
• Ramiro Ribeiro · June 30, 2026 · Sale

  2.4K @ $15
• George Elston · May 25, 2026 · Option Exercise

  7.5K
• George Elston · May 25, 2026 · Tax Withholding

  3.6K @ $12.93
• Ramiro Ribeiro · April 17, 2026 · Option Exercise

  2.4K @ $8.26
• Ramiro Ribeiro · April 17, 2026 · Sale

  2.4K @ $15
• Jay S. Duker · March 23, 2026 · J

  97.5K @ $9.57
• Jay S. Duker · March 23, 2026 · J

  52.5K @ $8.75
• Jay S. Duker · March 23, 2026 · J

  76.8K @ $13.11

Institutional Ownership

March 31, 2026

Total shares held

88.92M

Total value held

$1.14B

Institutional holders

183